Kenvue Inc. (NYSE:KVUE) Shares Sold by Ingalls & Snyder LLC

Ingalls & Snyder LLC decreased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 7.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 711,680 shares of the company’s stock after selling 59,662 shares during the period. Ingalls & Snyder LLC’s holdings in Kenvue were worth $15,194,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Leo Wealth LLC increased its position in shares of Kenvue by 0.3% in the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock worth $3,507,000 after acquiring an additional 481 shares in the last quarter. Alerus Financial NA increased its position in shares of Kenvue by 0.3% in the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock worth $4,426,000 after acquiring an additional 491 shares in the last quarter. Kiley Juergens Wealth Management LLC increased its position in shares of Kenvue by 1.9% in the fourth quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company’s stock worth $579,000 after acquiring an additional 500 shares in the last quarter. Principle Wealth Partners LLC increased its position in shares of Kenvue by 3.7% in the fourth quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company’s stock worth $303,000 after acquiring an additional 500 shares in the last quarter. Finally, Wolff Wiese Magana LLC increased its position in shares of Kenvue by 0.7% in the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Trading Up 0.2 %

Kenvue stock opened at $20.96 on Thursday. The firm’s 50-day moving average is $21.41 and its 200-day moving average is $22.03. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a market cap of $40.19 billion, a P/E ratio of 39.55, a PEG ratio of 2.16 and a beta of 1.45.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts expect that Kenvue Inc. will post 1.05 earnings per share for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th will be given a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.91%. Kenvue’s payout ratio is currently 154.72%.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on KVUE shares. UBS Group decreased their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Piper Sandler upgraded shares of Kenvue from a “neutral” rating to an “overweight” rating and upped their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. Royal Bank of Canada reiterated a “sector perform” rating and set a $24.00 price objective on shares of Kenvue in a research note on Monday, February 3rd. Finally, Bank of America increased their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, eight have given a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $23.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.